TickerTalks
Browse all tickers →
TickerTalks›$NTLA
NTNTLA

Intellia Therapeutics, Inc.

$NTLA·$1.6B·Biotechnology·Healthcare
$11.51-3.0%YTD+28.5%1Y-0.8%
Mentions · last 7 days
2026-07-10: 78 posts2026-07-11: 20 posts2026-07-12: 41 posts2026-07-13: 128 posts2026-07-14: 120 posts2026-07-15: 171 posts2026-07-16: 153 posts719+39%
Price updated 1m ago·X counts updated 22h ago
NTNTLA
$NTLAIntellia Therapeutics, Inc.
$11.51-2.99%719 posts+39%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $NTLA, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Driven by hypeCooling offAI verdict · as of 2026-07-16

Catching its breath after a run — could pick back up or fade from here.

Gene-editing leader up 41% YTD but rattled by AZN's Wainua fail — Q2 earnings August 6.

Intellia Therapeutics is one of the CRISPR-based gene-editing companies — most prominently developing in-vivo editing for hereditary angioedema (NTLA-2002) and TTR-CM (NTLA-2001). The stock is up 41% YTD but has cooled after AstraZeneca's Wainua Phase 3 failure raised questions about the TTR-CM approach broadly.

  • Revenue was down 9% YoY last quarter with a -668% operating margin — this is a clinical-stage biotech with no meaningful revenue; the equity value is entirely a bet on the pipeline hitting.
  • Trades at 23x TTM sales on nominal revenue — meaningless multiple math; the valuation is really a probability-weighted call on NTLA-2002 approval and NTLA-2001 succeeding where Wainua failed.
  • The Wainua CARDIO-TTRansform failure raises real concerns about the TTR-CM silencer approach — bears reasonably argue this could put NTLA-2001 'dead in the water' if the mechanism doesn't distinguish itself.
  • Modest CFO Edward Dulac and controller Michael Dube sales of $84K + $44K on July 6 — small distributions but the timing raises attention.
  • 52-week position 25th percentile with position vs 200-day MA -5% — the tape hasn't fully broken but is under pressure post-Wainua.

August 6 Q2 earnings is where the pipeline case either extends or contracts: specific NTLA-2001 Phase 2 data readout timing plus differentiation-from-Wainua commentary is what confirms the run; more Wainua-comparison concerns or a delayed pipeline event is where the tape breaks new lows below $10. Real gene-editing platform with real Wainua-related uncertainty — the setup rewards specific pipeline execution over narrative.

Agrees with X sentimentThe mixed X read on NTLA leading gene-editing 'closest to commercial reality' alongside the Wainua-related concerns for NTLA-2001 is analytically fair. The Helios B combo NT-proBNP data improvement is a real positive; the 'dead in the water' bear framing is a specific risk that Q2 has to address.

What to watch: Aug 6 Q2 earnings — need specific NTLA-2001 Phase 2 data readout timing and clear differentiation-from-Wainua commentary. More Wainua-comparison concerns is where the tape breaks below $10.

On the calendar: 2026-08-06 — Q2 earnings

float missingbeta missing

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Mixed sentiment⚠12 posts analyzed · as of 2026-07-15 · top-engagement diverged

Intellia Therapeutics chatter is split. Bulls point to NTLA leading the gene-editing 'closest to commercial reality' order (NTLA > BEAM > CRSP > PRME > EDIT) and note improvements in Helios B combo NT-proBNP data. Bears reason that AZN's CARDIO-TTRansform Wainua Phase 3 failure could mean NTLA's TTR-CM program is 'dead in the water' if silencer-approach is broken. Community notes braindead investor reactions to platform stocks like NTLA and ALNY. NTLA slid 7.4% on 3.68M shares with no clear news. Sentiment cautious.

Read the AI verdict + X sentiment for $NTLA

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Develops in vivo CRISPR-Cas9 gene editing therapies for ATTR amyloidosis and other systemic genetic diseases.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $NTLA.

Biotechnology · Healthcare

No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.

What this means for $NTLA

Neutral — Develops in vivo CRISPR-Cas9 gene editing therapies for ATTR amyloidosis and other systemic genetic diseases; this business's revenue is largely decoupled from the GLP-1 pipeline bifurcation and ADA oral formulation competition.

Top industry ETF

$IBBiShares Biotechnology ETF
+11.7%YTD
+44.5%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-4.1How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-60.0%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-6.4%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-23.9%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
23.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-57.3%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
-31.9%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.1Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026May 11, 2026$-0.81$-0.92+12.0%
Q4 2025Feb 26, 2026$-0.83$-0.99+16.2%
Q3 2025Nov 6, 2025$-0.92$-1.02+9.8%
Q2 2025Aug 7, 2025$-0.99$-1.03+3.9%
Next earningsThu, Aug 6·consensus EPS $-0.80

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$15.0M-9.5%85.4%-668%$-0.81$-117.4M
Q4 FY25$23.0M+78.8%73.9%-429%$-0.83$-69.4M
Q3 FY25$13.8M+51.3%-473%-809%$-0.92$-76.9M
Q2 FY25$14.2M+104.8%100%-772%$-0.98$-99.9M

Forward consensus

5-year forecast · up to 15 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$58.7M$14.2M – $94.6M-$3.19-$3.56 – -$2.7715
FY27$274.8M$2.0M – $1.7B-$1.76-$8.44 – $35.1515
FY28$690.7M$682.7M – $698.6M-$0.51-$9.62 – $41.7713
FY29$1.7B$72.9M – $12.2B$4.11-$1.01 – $36.1612
FY30$2.7B$114.0M – $19.0B$8.97-$2.20 – $78.806

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.1×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.19%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-16.7%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-13.0%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 106.2M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today6.1% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.775-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.FilingActive offeringA shelf registration (S-3 / S-3ASR / S-1) or prospectus supplement (424B*) was filed in the last 90 days — the company is registered to (or actively) issuing new shares. Dilution risk.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellJul 2Edward J DulacCFO4.7K sh$84KSellJul 1Michael P DubeVP, Chief Accounting Officer2.6K sh$44KSellMar 2James BastaEVP, General Counsel1.2K sh$17KSellMar 2Eliana ClarkEVP, Chief Technical Officer607 sh$8K
+ 14 other (14 awards) in window

See when $NTLA insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KPress release / Reg FDJun 158-K — Item 7.01: Press release / Reg FD · Item 8.01: Other event
AI summary

Intellia Therapeutics, Inc. (NTLA) made a Reg FD disclosure (Item 7.01) and reported other events (Item 8.01) in an 8-K filed June 15, 2026. Body unavailable — excerpt cuts off before the substance of the Reg FD disclosure is revealed.

8-KShareholder voteJun 108-K — Item 5.07: Shareholder vote
AI summary

Intellia Therapeutics held its 2026 Annual Meeting on June 9, 2026, with three proposals voted on by shareholders. Class I directors Muna Bhanji and Brian Goff were elected (Jesse Goodman passed with a thinner margin — 43M for vs. 15.7M against), Deloitte & Touche LLP was ratified as independent auditor for fiscal year ending December 31, 2026, and named executive officer compensation was approved on a non-binding advisory basis (44.8M for, 13.8M against). Goodman's higher withhold vote (~27% against) is a notable governance signal worth monitoring. Routine annual meeting with no material financial or strategic implications.

8-KMaterial agreementApr 308-K — Item 1.01: Material agreement · Item 2.02: Earnings release
AI summary

NTLA reported period ending 2026-04-30 financial results (8-K Item 2.02). Investors should review the full earnings press release and any management guidance for forward outlook.

424B5Prospectus supplement (offering)Apr 29424B5
AI summary

NTLA filed a 424B5 prospectus supplement dated 2026-04-29, representing an active capital markets transaction. Priced at $15.87 per share. This represents immediate dilution to existing shareholders.

424B5Prospectus supplement (offering)Apr 27424B5
AI summary

NTLA filed a 424B5 prospectus supplement dated 2026-04-27, representing an active capital markets transaction. Priced at $15.87 per share. This represents immediate dilution to existing shareholders.

8-KPress release / Reg FDApr 278-K — Item 7.01: Press release / Reg FD · Item 8.01: Other event
AI summary

NTLA filed an 8-K Item 7.01 (Reg FD) disclosure dated 2026-04-27. Covers: presented topline data from the HAELO Phase 3 trial of lonvoguran ziclumeran (“lonvo-z”) for the tre. Reg FD disclosures make material information simultaneously available to all investors; content may include guidance updates, strategic plans, or preliminary results.

8-KCharter amendmentApr 108-K — Item 5.03: Charter amendment
AI summary

NTLA filed an 8-K (Item 5.03) dated 2026-04-10. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On April 7, 2026, based on the recommendation of the nominating and corporate governance committee of the board of directors (the “Board”) of Intellia Therapeutics, Inc.

424B5Prospectus supplement (offering)Mar 2424B5
+ 18 other (8 13Gs · 2 earnings 8-Ks · 2 proxys · 2 8-Ks) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

NTLA Surges 38% in a Month: Should You Buy, Sell or Hold the Stock?zacks.com·8d agoA New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR Therapeuticsfool.com·10d agoIntellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com·11d agoWall Street Thinks This High-Flying Biotech Stock Can Soar Another 57%fool.com·16d agoPowder Keg Stocks: 10 Most‑Shorted Names Primed For A Monster Squeezebenzinga.com·18d ago

In themes

Explore the broader themes this ticker is being talked about under.

Gene Editing & CRISPR

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$SEER$QTTB$AGEN$REGN$MRNA$SLS$AURA$ATAI
Voices on X · top 1 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport